AZN vs. TEVA: AstraZeneca vs. Teva Pharmaceutical Stock Comparison
How do AstraZeneca (AZN) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AstraZeneca (AZN) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Both AstraZeneca (AZN) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.
| Profile Item | AZN | TEVA |
|---|---|---|
| Name | AstraZeneca PLC American Depositary Shares | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | United Kingdom | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 289.14 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 12, 1993 | February 16, 1982 |
| Security Type | ADR | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Total Return (1Y) | 12.64% | 79.58% |
| Total Return (3Y, Annualized) | 15.75% | 69.94% |
| Total Return (5Y, Annualized) | 10.63% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 28.21% | 33.95% |
| Beta (5Y) | 0.22 | 0.96 |
| Max Drawdown (5Y) | -27.87% | -43.70% |
| Avg. Volume (3M) | 3.14M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.30 | 2.22 |
| Sortino Ratio (1Y) | 0.44 | 3.94 |
Profitability
ROE (TTM)
Both AstraZeneca (AZN) at 22.57% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.57%
- Max
- 109.18%
- AZN
- 22.57%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
AstraZeneca (AZN) at 17.68% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.68%
- Max
- 18.05%
- AZN
- 17.68%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AstraZeneca (AZN) at 29.57% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.57%
- Max
- 83.12%
- AZN
- 29.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AZN | TEVA |
|---|---|---|
| ROE (TTM) | 22.57% | 6.65% |
| ROA (TTM) | 8.59% | 5.35% |
| Net Margin (TTM) | 17.68% | 2.94% |
| Operating Margin (TTM) | 29.57% | 27.40% |
| Gross Margin (TTM) | 81.78% | 53.51% |
Growth
Revenue Growth
Both AstraZeneca (AZN) at 8.63% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: AstraZeneca (AZN) reports EPS growth of 45.33%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 4.31% |
| Revenue Growth (3Y CAGR) | 9.82% | 4.96% |
| EPS Growth (YoY) | 45.33% | -- |
| EPS Growth (3Y CAGR) | 45.80% | -- |
Financial Strength
Current Ratio (MRQ)
Both AstraZeneca (AZN) at 1.01 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AZN
- 1.01
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: AstraZeneca (AZN) at 0.66 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.66
- Max
- 1.42
- AZN
- 0.66
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 0.95 |
| Debt / Equity (MRQ) | 0.66 | 2.13 |
| Net Debt / EBITDA | 1.23 | 2.93 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73%
- AZN
- 1.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.38%
- AZN
- 45.38%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AZN | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.00% |
| Dividend Payout Ratio (TTM) | 45.38% | 0.00% |
Valuation
P/E Ratio (TTM)
AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.37
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- AZN
- 26.37
- Q1
- 13.30
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while AstraZeneca (AZN) at 4.63 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AZN
- 4.63
- Q1
- 3.01
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both AstraZeneca (AZN) at 5.59 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.59
- Max
- 13.53
- Q3
- 6.54
- AZN
- 5.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AZN | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 26.37 | 99.09 |
| P/S Ratio (TTM) | 4.63 | 2.89 |
| P/B Ratio (MRQ) | 5.59 | 6.23 |
| Free Cash Flow Yield (TTM) | 1.95% | 3.00% |